ADA 2026 Final Day: Pfizer's Berobenatide Delivers 12.3% Weight Loss as First Monthly GLP-1 RA, Orforglipron Shows Significant Weight Loss Across All Menopause Stages, ASC30 Oral GLP-1 Posts 7.7% Weight Loss at 13 Weeks — June 8, 2026 Peptide Research Update
Table of Contents
- ADA 2026 Day 4: The Closing Session's Three Defining Stories
- Berobenatide: The First Once-Monthly GLP-1 RA Posts 12.3% Placebo-Adjusted Weight Loss at 28 Weeks
- Why Monthly Dosing Could Reshape GLP-1 Adherence — and the Competitive Landscape
- Orforglipron at Every Menopausal Stage: ATTAIN Subanalysis Shows Up to 30.4 lbs Weight Loss in Peri-Menopausal Women
- ACHIEVE-2 and ACHIEVE-5: Orforglipron's T2D Phase 3 Program Completes the Profile
- ASC30: China's Oral GLP-1 Challenger Posts 7.7% Weight Loss at 13 Weeks with 2–3x Greater In Vitro Potency
- ADA 2026 Full Conference Synthesis: What Four Days of Data Mean for the 2026–2028 Obesity Pipeline
ADA 2026 Day 4: The Closing Session's Three Defining Stories
The final day of the American Diabetes Association's 86th Scientific Sessions (June 8, 2026, New Orleans) brought a set of data that reframe near-term obesity drug competition along three axes: dosing convenience, population-specific efficacy, and the emerging oral GLP-1 challenger tier. Pfizer presented the most complete dataset yet for berobenatide — a once-monthly injectable GLP-1 RA positioned as the first major break from the weekly injection standard set by semaglutide and tirzepatide. Eli Lilly expanded orforglipron's (Foundayo's) clinical story with menopausal subgroup analyses and ACHIEVE T2D Phase 3 data, cementing the drug's position as the complete oral GLP-1 option across demographics. And Ascletis Pharma introduced ASC30, an oral small-molecule GLP-1R agonist with higher in vitro potency than orforglipron, into the public clinical data record for the first time. Together, these datasets close ADA 2026 with a clear message: the next generation of obesity drugs will compete not just on efficacy magnitude, but on dosing convenience, population fit, and administration simplicity.
Berobenatide: The First Once-Monthly GLP-1 RA Posts 12.3% Placebo-Adjusted Weight Loss at 28 Weeks
Berobenatide is an investigational injectable GLP-1 RA developed by Metsera and acquired by Pfizer for ~ billion in November 2025. Its core differentiation is dosing interval: where Wegovy and Zepbound require weekly injections, berobenatide is designed for once-monthly subcutaneous injection via fatty acid conjugation that extends the drug's half-life across a 30-day dosing window. The Phase 2b VESPER-3 trial enrolled adults with obesity (no T2D) and tested weekly-to-monthly escalation schedules up to 4.8 mg monthly. At 28 weeks, the 4.8 mg monthly dose achieved 12.3% placebo-adjusted weight loss with no evidence of a plateau — the most critical finding for investor and clinical confidence. A 32-week exploratory extension showed non-placebo-adjusted weight loss of 15.9% in participants who escalated from placebo to 2.4 mg weekly berobenatide, with the trajectory still rising at week 32. For type 2 diabetes, VESPER-1 data showed 10.2% weight loss alongside a 2.2 percentage-point blood glucose reduction at 28 weeks. The tolerability profile was directly compared with weekly semaglutide: 83% of treated participants reported no or only mild key GI adverse events, with GI effects largely clustered near injection dates and decreasing over time — a pattern Pfizer characterized as consistent with the GLP-1 RA class standard set by Wegovy. Pfizer announced plans to initiate 10 Phase 3 trials in 2026 covering chronic weight management, knee osteoarthritis, and obstructive sleep apnea — a scope that signals significant commercial ambition for the monthly format.
Why Monthly Dosing Could Reshape GLP-1 Adherence — and the Competitive Landscape
Real-world GLP-1 adherence data consistently show 12-month discontinuation rates of 50–65% for weekly injectables, with injection burden cited as a primary driver of early dropout, particularly in populations unfamiliar with self-injection. If berobenatide's Phase 3 program confirms the Phase 2b efficacy trajectory — ideally reaching 18–20% weight loss at full dose over 72 weeks — the monthly format could become a structural advantage over weekly competitors rather than just a convenience option. The 12.3% weight loss at 28 weeks is lower than leading weekly injectables (semaglutide 2.4 mg: ~15% at 68 weeks; tirzepatide 15 mg: ~22% at 72 weeks), but the plateau-free trajectory and 32-week extension data suggest the gap may narrow with longer treatment. The T2D dataset adds a second indication for Phase 3 development. Pfizer's decision to pursue 10 simultaneous Phase 3 programs reflects the same multi-indication strategy Novo Nordisk and Lilly used to accelerate semaglutide and tirzepatide — and positions berobenatide as a platform product rather than a single-indication drug. The next key readout will be Phase 3 dose-ranging results, expected in 2027-2028.
Orforglipron at Every Menopausal Stage: ATTAIN Subanalysis Shows Up to 30.4 lbs Weight Loss in Peri-Menopausal Women
Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 Phase 3 trials presented at ADA 2026 provide the first systematic breakdown of orforglipron efficacy by menopausal status — addressing one of the most clinically relevant questions in obesity pharmacology, given that hormonal transitions in perimenopause are a primary driver of weight gain and treatment-resistant obesity in women aged 40–55. In ATTAIN-1 (women with obesity, no T2D), participants on the highest orforglipron dose lost 28.0 lbs (12.8%) if pre-menopausal, 30.4 lbs (14.4%) if peri-menopausal, and 28.2 lbs (14.1%) if post-menopausal — with 51.5% of participants in ATTAIN-1 achieving ≥15% weight loss. The peri-menopausal response (30.4 lbs) being highest is a clinically notable finding, potentially reflecting greater relative weight reduction opportunity in women experiencing active hormonal-driven adiposity shifts. In ATTAIN-2 (women with obesity + T2D), weight loss was 23.4 lbs (11.3%), 18.5 lbs (8.9%), and 27.8 lbs (13.6%) for pre-, peri-, and post-menopausal participants respectively, with 44.2% achieving ≥15% weight loss. Waist circumference reductions of up to 4.9 inches (ATTAIN-1) and 4.3 inches (ATTAIN-2) were also observed. These subanalysis data are important not just for prescribing but for positioning: they establish Foundayo as the first FDA-approved oral GLP-1 with published Phase 3 menopausal subgroup data, enabling evidence-based conversations with the 50+ million U.S. women in peri- or post-menopausal status who represent a high-priority obesity treatment demographic.
ACHIEVE-2 and ACHIEVE-5: Orforglipron's T2D Phase 3 Program Completes the Profile
Alongside the menopausal data, Lilly presented Phase 3 ACHIEVE program results for T2D, completing the evidence package for the expected T2D indication approval. ACHIEVE-2 randomized adults with T2D to orforglipron vs dapagliflozin (an SGLT2 inhibitor currently first-line in T2D) over 40 weeks; orforglipron lowered A1C by up to 1.7% compared with 0.8% for dapagliflozin — a clinically meaningful and statistically significant difference that positions orforglipron above the most commonly prescribed T2D non-insulin class. ACHIEVE-5 tested orforglipron as an add-on to titrated insulin glargine vs placebo + insulin over 40 weeks; orforglipron delivered A1C reductions of up to 2.1% vs 0.8% with placebo — establishing its efficacy even in insulin-requiring patients. Together with the previously published ACHIEVE-3 data (orforglipron superior to oral semaglutide: A1C −2.2% vs −1.4%, weight −19.7 lbs vs −11.0 lbs), the ACHIEVE program establishes orforglipron as effective across the T2D treatment spectrum — from early add-on to dapagliflozin through insulin-augmentation. The FDA T2D indication review is expected to complete in H2 2026.
ASC30: China's Oral GLP-1 Challenger Posts 7.7% Weight Loss at 13 Weeks with 2–3x Greater In Vitro Potency
Ascletis Pharma's ASC30 is the most potent oral GLP-1R agonist to enter clinical data at ADA 2026. The compound uses Ascletis's POTENT (Peptide Oral Transport ENhancement Technology) scaffold — a proprietary non-peptide chemistry platform — and demonstrated in vitro GLP-1 receptor potency approximately 2–3 times higher than orforglipron in head-to-head receptor binding and cAMP assays. Phase 2 data from an n=125 study showed dose-dependent placebo-adjusted weight reductions at week 13 of 5.4% (20 mg), 7.0% (40 mg), and 7.7% (60 mg), with no weight loss plateau observed across any dose group. If the 2–3x in vitro potency advantage translates to proportionally greater weight loss in Phase 3-scale trials, ASC30 could deliver weight loss comparable to aleniglipron (which showed 16.3% at 44 weeks) or exceed orforglipron's ATTAIN-1 peak of 11.2% at 72 weeks. The GI tolerability profile was reported favorably in comparison with orforglipron in Ascletis's own assays, attributed to the compound's biased agonism toward cAMP-mediated signaling over beta-arrestin recruitment. Ascletis also presented preclinical data for ASC39, a selective amylin type 1 receptor (hAMY1R) agonist with minimal calcitonin receptor binding — designed to mimic the amylin mechanism without the nausea associated with calcitonin receptor activation. ASC39 produced 9.9% body weight reduction vs 2.8% placebo in a diet-induced obesity rat model. The U.S. clinical development path for ASC30 and ASC39 has not yet been confirmed, but the ADA 2026 data represent their first appearance in the international clinical literature.
ADA 2026 Full Conference Synthesis: What Four Days of Data Mean for the 2026–2028 Obesity Pipeline
ADA 2026 has now concluded as the most data-dense single conference in obesity pharmacology history. Across four days, at least ten significant peptide datasets were presented spanning five receptor targets and three dosing formats (subcutaneous weekly, subcutaneous monthly, oral daily). The major developments that will shape the field through 2028 are: (1) Retatrutide as the 28%+ efficacy ceiling, with Phase 3 OA data now supporting a potential supplemental musculoskeletal indication; (2) Berobenatide establishing monthly dosing as clinically viable and adherence-competitive — Phase 3 results will determine whether it can match weekly agents on 72-week weight loss trajectories; (3) Orforglipron's menopause subgroup data and ACHIEVE T2D Phase 3 evidence establishing Foundayo as the complete oral option, not simply an injection-free compromise; (4) The amylin axis — validated simultaneously through CagriSema (fMRI), zenagamtide (T2D Phase 2), petrelintide (ZUPREME-1 full cardiometabolic), and ASC39 (preclinical) — as the strongest mechanistic differentiation theme in the entire obesity pipeline; (5) The oral GLP-1 competitive field intensifying beyond Foundayo, with ASC30's higher in vitro potency and aleniglipron's 16.3% 44-week efficacy presenting credible long-term challenges. The next 12 months will deliver Phase 3 data for berobenatide, survodutide FDA decision (Q3 2026), retatrutide NDA (Q4 2026), and Phase 3 initiations for zenagamtide and aleniglipron — making 2026-2027 the most consequential regulatory period the obesity drug field has ever seen.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
Related Articles
The ADA 2026 Scientific Sessions open today in New Orleans (June 5–8) with an unprecedented density of late-stage obesity and diabetes pipeline data: Eli Lilly presents full TRIUMPH-1 retatrutide data (28.3% weight loss, 80 wks), Boehringer Ingelheim presents complete SYNCHRONIZE-1 survodutide results (16.6% vs 3.2% placebo, 76 wks), Novo Nordisk hosts a REIMAGINE 1–3 symposium for CagriSema in T2D, and presents zenagamtide Phase 2 data (up to 24.3% weight loss) as its next-generation GLP-1/amylin molecule.
ADA 2026 Day 2: Petrelintide Full ZUPREME-1 Data Confirms Cardiometabolic Benefits and Phase 3 Path, DA-1726 Posts Three Abstracts — June 6, 2026 Peptide Research Update
ADA 2026 Day 2 in New Orleans brings full ZUPREME-1 body composition and cardiometabolic data for petrelintide (Zealand/Roche) — confirming hsCRP reductions of 17–41%, triglyceride reductions of 12–21%, and waist circumference improvements of up to 10.8 cm, all with placebo-like tolerability — alongside three MetaVia DA-1726 late-breaking poster abstracts covering final MAD data, lean mass preservation, and direct hepatic FibroScan endpoints.
ADA 2026 Day 3: Retatrutide TRIUMPH-4 shows 28.7% weight loss plus 75.8% WOMAC knee pain reduction — highest pain relief in any obesity-OA drug trial. Zenagamtide (amycretin) posts 14.6% weight loss and 89% A1C target achievement in Phase 2 T2D, triggering Phase 3 T2D program for H2 2026. CagriSema functional brain imaging reveals the amylin+GLP-1 appetite-circuit mechanism behind its 22.7% weight loss.
ASC39: An Oral Amylin Pill Aiming to Match Injectable Amylin Drugs (July 30, 2026)
The best amylin obesity drugs are injections. ASC39, from Ascletis, is a once-daily pill that matched Eli Lilly's injectable eloralintide on amylin potency, selectivity and weight loss in preclinical tests - and it is being paired with an oral GLP-1 agonist into a single tablet. Here is what is known, and what is not.